Endres Bradley T, Bassères Eugénie, Alam M Jahangir, Garey Kevin W
a Department of Pharmacy Practice and Translational Research , University of Houston College of Pharmacy , Houston , TX , USA.
Expert Opin Investig Drugs. 2017 Apr;26(4):509-514. doi: 10.1080/13543784.2017.1304538.
Antibiotic development goals for CDI include potent antimicrobial effect against C. difficile, limited killing of host microbiota, potential effect on spores, and ability to interfere with toxin production. Cadazolid, a novel, non-absorbable hybrid antibiotic has many of these criteria. In phase I and II clinical trials, cadazolid was shown to be safe, well tolerated, and efficacious positioning itself as a potential future viable therapeutic option for CDI. Areas covered: This review provides an in-depth evaluation of the chemistry, microbiology, pharmacodynamics, pharmacokinetics, and clinical trial results for cadazolid. Clinical therapeutic outcomes are compared between cadazolid, fidaxomicin, and surotomycin. Expert opinion: Preclinical and early clinical studies demonstrated that cadazolid has unique properties that will likely be valuable to treat CDI and reduce recurrent infection. With compelling phase II clinical results, results from the ongoing phase III trial will better define the role of cadazolid for treating CDI in the future.
艰难梭菌感染（CDI）的抗生素研发目标包括对艰难梭菌有强大的抗菌作用、对宿主微生物群的杀伤有限、对孢子有潜在作用以及干扰毒素产生的能力。新型非吸收性混合抗生素卡达唑胺符合其中许多标准。在I期和II期临床试验中，卡达唑胺被证明是安全的，耐受性良好且有效，使其成为CDI未来潜在的可行治疗选择。涵盖领域：本综述对卡达唑胺的化学、微生物学、药效学、药代动力学和临床试验结果进行了深入评估。比较了卡达唑胺、非达霉素和苏罗霉素的临床治疗结果。专家观点：临床前和早期临床研究表明，卡达唑胺具有独特的特性，可能对治疗CDI和减少复发感染有价值。鉴于令人信服的II期临床结果，正在进行的III期试验结果将更好地确定卡达唑胺未来在治疗CDI中的作用。
